FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

١	Nas	hing	ton,	D.C.	20549	

	OMB APPROVAL												
	OMB Number:		3235-028										
- 1													

37 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Clancy Paul J (Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET				2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 05/31/2018							(Ch	elationship of Reporting Perseck all applicable) X Director Officer (give title below)			son(s) to Iss 10% Ov Other (s below)	ner		
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)							Lind	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transacti Code (Ins 8)	ion 5	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5) Amount (A) or (D) P		ed (A) or str. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership Instr. 4)			
1. Title of Derivative Conversion Security or Exercise (Month/Day/Year) Garage 3. Transaction Date Execution Date, if any		.g., pu	ts, calls, warrants, or sansaction of Derivative (N					7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Co	ode '	v	(A)	(D)	Date Exercisable	Expi Date	iration e	Title	or Number of Shares					
Stock option (right to buy)	\$93.5	05/31/2018			A		5,700		(1)	05/3	30/2028	Common stock	5,700	\$0.00	5,700		D	
Restricted stock units	(2)	05/31/2018			A		1,400		(3)		(3)	Common stock	1,400	\$0.00	1,400		D	

Explanation of Responses:

- 1. This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019.
- 2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 3. The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Remarks:

/s/ William Cook, as Attorney-06/04/2018 in-fact for Paul Clancy

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.